Disc Medicine, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-212.2M | $-109.4M | $-76.4M | $-46.8M | $-36.0M | $-40.8M |
| Depreciation & Amortization | $281.0K | $156.0K | $100.0K | $89.0K | $32.0K | — |
| Depreciation | — | $200.0K | $100.0K | — | $231.0K | $322.0K |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $34.3M | $16.8M | $5.5M | $2.1M | $507.0K | $983.0K |
| Net Cash from Operating Activities | $-180.4M | $-93.9M | $-73.5M | $-42.3M | $-27.5M | $-32.7M |
| Investing Activities | ||||||
| Capital Expenditures | $933.0K | $505.0K | $89.0K | $151.0K | $68.0K | $22.0K |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-394.3M | $-292.3M | $-89.0K | $-151.0K | $-68.0K | $-22.0K |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $473.4M | $218.3M | $239.4M | $149.0M | $89.9M | $34.2M |
| Net Change in Cash | $-101.3M | $-167.9M | $165.8M | $106.6M | $62.3M | $1.5M |
| Free Cash Flow | $-181.3M | $-94.4M | $-73.6M | $-42.4M | $-27.6M | $-32.7M |